AVALO THERAPEUTICS INC (AVTX)

Company Profile

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. The company is headquartered in Rockville, Maryland and currently employs 20 full-time employees. The company went IPO on 2015-11-13. The firm is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. Its clinical-stage pipeline includes AVTX-002, AVTX-008, and AVTX-803 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders. AVTX-803 is a monosaccharide therapy for the treatment of leukocyte adhesion deficiency type II (LAD II), which is a congenital disorder of glycosylation (CDG).

Company Info

AVALO THERAPEUTICS INC

540 Gaither Rd Ste 400

Rockville MARYLAND

P: 14105228707.0

CEO: Michael Cola

Employees: 20

Website: https://www.avalotx.com/